Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18754465 | 0.90 | TSHR (0.44) | TSHRHDAC6HDAC1HDAC8GSK3A | |
| SCHEMBL31589839 | 0.79 | TSHR (0.46) | TSHRHDAC6HDAC1HDAC8GSK3A | |
| SCHEMBL3968679 | 0.76 | TSHR (0.43) | TSHRHDAC6HDAC1HDAC8GSK3A | |
| SCHEMBL8589410 | 0.75 | TSHR (0.46) | TSHRHDAC6HDAC1HDAC8GSK3A | |
| SCHEMBL8442458 | 0.75 | TSHR (0.46) | TSHRHDAC6HDAC1HDAC8GSK3A | |
| SCHEMBL17160685 | 0.75 | TSHR (0.42) | TSHRHDAC6HDAC1HDAC8GSK3A | |
| SCHEMBL2411658 | 0.74 | TSHR (0.48) | TSHRHDAC6HDAC1HDAC8GSK3A | |
| SCHEMBL11726006 | 0.72 | CHRM2 (0.48) | TSHRHDAC6HDAC1HDAC8MAOA | |
| SCHEMBL16116451 | 0.72 | — | — | |
| SCHEMBL8588869 | 0.71 | CHRM2 (0.62) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5852029-A | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1998-12-22 | — | — | US | claimed |
| JP-5255271-A | — | — | None | — | — | JP | disclosed |
| EP-2677318-B1 | LABELING AGENT FOR POST-TRANSLATIONAL MODIFICATION ANALYSIS OF SERINE AND THREONINE | CELLSEED INC (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-20140024124-A1 | LABELING AGENT FOR ANALYZING POST-TRANSLATIONAL MODIFICATIONS OF SERINE AND THREONINE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2014-01-23 | — | — | US | disclosed |
| EP-2677318-A1 | LABELING AGENT FOR POST-TRANSLATIONAL MODIFICATION ANALYSIS OF SERINE AND THREONINE | CellSeed Inc. (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1926712-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1926712-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007028131-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028131-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-0560581-B1 | Process for producing 3-hydroxymethyl-1-propargyl-imidazolidine-2,4-dione | SUMITOMO CHEMICAL CO (JP) | 2000-06-07 | — | — | EP | disclosed |
| JP-H05255271-A | PRODUCTION OF 3-HYDROXYMETHYL-1-PROPARGYLIMIDAZOLIDINE-2,4-DIONE | SUMITOMO CHEM CO LTD | 1993-10-05 | — | — | JP | disclosed |
| EP-0440670-A1 | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. | UPJOHN CO (US) | 1991-08-14 | — | — | EP | disclosed |
| EP-0285270-A1 | A method for producing 1-propargyl-2,4-dioxoimidazolidine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | HTR2C, HTR2A, HTR1A | TSHR 107/4885HDAC6 2142/4885HDAC1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.